You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3Disease Modeling
Ex Vivo Assays
Ex vivo immunology assays are an important tool in preclinical drug discovery and development. Performed on extracted tissues from diseased and non-diseased animals, they can help provide essential data about drug behavior, including toxicity and potential side effects, before animal or human testing proceeds. This detailed mechanistic information at the cellular or tissue level enables researchers to make critical decisions to continue or terminate earlier in the drug discovery process prior to animal studies or human clinical trials.
- Biomarker analysis of diseased tissue in the context of a disease organs such as paw, skin, brain, spinal cord, liver and others
- Multiplex analyses of cytokines, hormones, and other analytes
- Flow cytometry analysis
- Gene expression analysis by PCR and RT-qPCR
- Proliferative responses of immune T cells
- by anti-CD3/anti-CD28
- Proliferative responses of immune B cells
- Cytokine production
- By T cells after primary and secondary stimulation by anti-CD3/CD28
- By monocytes after LPS stimulation
Learn more about